Drug Trial Radar · NCT06908772
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Last checked: Nov 20, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Apr 1, 2025
Primary completion
Dec 31, 2028
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.
Conditions
- Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Interventions
Glumetinib TabletsDrug
An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
Osimertinib Mesylate TabletsDrug
3rd EGFR-TKI
Glumetinib Tablets PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2:ORR as assessed by IRCTime frame: Up to approximately 30 months after the first participant is enrolled
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.